Navigation Links
UH Seidman Cancer Center researchers present at American Society of Hematology Annual Meeting
Date:12/10/2011

says Dr. Distelhorst, who is vice-chair of the ASH subcommittee on Lymphoid Neoplasia. "This is a major step forward in our research efforts to develop new therapies for lymphoid malignancies."

Dr. Distelhorst's session is Saturday, December 10, 4 p.m. - 5:30 p.m. in Room 6A. (San Diego Convention Center). http://ash.confex.com/ash/2011/webprogram/Paper35836.html

In a poster presentation (Abstract# 1907), Jeffery Auletta, MD, Kenneth Cooke, MD, and colleagues presented significant findings that mesenchymal stem cells (MSCs) effectively treat graft-versus-host disease (GvHD) while not interfering with bone marrow transplant's efficacy in treating leukemia.

MSCs are non-hematopoietic (not blood-forming cells) adult stem cells found in the bone marrow and were discovered at UH Seidman Cancer Center and Case Western Reserve University. They maintain hematopoietic stem cell (blood-forming cells) development and also differentiate into fat cells, bone cells and cartilage cells. MSCs have been shown to suppress immune responses ex vivo (outside the body in cell culture conditions).

Due to these properties, MSCs have been used to treat GvHD in bone marrow transplant (BMT) patients. However, how MSC immunomodulation works in vivo (inside the body) has not been well studied, and, in fact, could potentially promote leukemia/lymphoma recurrence in transplant patients. That is, the benefit of BMT is that the donor graft kills residual leukemia in the transplant recipient (host), a process called graft-versus-leukemia (GvL).

"We used a pre-clinical mouse model of BMT to study how human MSCs mediate in vivo immune effects," says Dr. Auletta. "Our results show for the first time using an animal model that human MSCs simultaneously attenuate GvHD, but spare GvL activity."

The poster titled "Human Mesenchymal Stem Cells Attenuate Graft-Versus-Host Di
'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-533-0685
University Hospitals Case Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. University Hospitals Seidman Cancer Center tests novel drug that makes brain tumors glow hot pink
2. Breast cancer treatment resistance linked to signaling pathway
3. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
4. The dietary supplement genistein can undermine breast cancer treatment
5. Saliva proteins could help detection of oral cancer
6. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
7. Breakthrough optical technology to assess colon cancer risk, accuracy
8. Breast cancer cells recycle to escape death by hormonal therapy
9. Nanodiamond drug device could transform cancer treatment
10. Second lumpectomy for breast cancer reduces survival rates
11. Study looks at psychological impact of gene test for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is ... Facial recognition system measures the overall facial feature ... mouth, and the distance between eyes. Facial recognition ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... , Dec. 9, 2014 CIE San Diego ... that provides the connective tissue that enhances care coordination ... to easily share client-level information; earned a second $1 ... to organizations serving seniors aging in community and; will ... on December 11 th 4-6p. CIE ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... changing climate there,s a good chance that forest fires in ... and according to one expert speaking today at a professional ... this region is difficult to predict, will always be variable, ... understand, however, that fire is not only inevitable but also ...
... NEW YORK (February 24, 2010) An international ... used mouse embryonic stem cells to replace diseased retinal ... retinitis pigmentosa. This strategy could potentially become a new ... that affects approximately one in 3,000 to 4,000 people, ...
... ensure that people with rare forms of cancer are not denied ... major European cancer conference to be held in Milan on 9 ... same right to receive proper treatment as all other patients", said ... at the Milan Istituto Nazionale Tumori and co-chair of the ESMO ...
Cached Biology News:More frequent fires could aid ecosystems 2More frequent fires could aid ecosystems 3Stem cells restore sight in mouse model of retinitis pigmentosa 2Stem cells restore sight in mouse model of retinitis pigmentosa 3'Rare' cancers in the spotlight at major European conference 2
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... , AMES, Iowa , ... technology company, announced that it will embark a $5.3 million ... $44 million DOE Investment for Advanced Biofuels Research and ... Advanced Biofuels and Bioproducts (NAABB).  Catilin and its partner, Iowa ...
... 2008 08/07 2009 ... MEUR %Sales Var.% MEUR %Sales Var.%, Southern Europe (1) 36.4 ... 11.3 23 17 13.1 23 16, ... 1.5 3 (25), SLIT ...
... , , ... AB (publ),and BioChromix AB announced today the formation of BioChromix Pharma ... its unique,knowledge of molecular chemistry. Karolinska Development will initially take,28 percent ... are very excited about BioChromix Pharma as they have a novel,approach ...
Cached Biology Technology:Catilin Contributes Key Extraction, Sequestration and Conversion Technologies to NAABB Consortium Developing Algal Biofuels 2Catilin Contributes Key Extraction, Sequestration and Conversion Technologies to NAABB Consortium Developing Algal Biofuels 3STALLERGENES : Sales Guidance Exceeded : EUR193 Million, up 13% 2STALLERGENES : Sales Guidance Exceeded : EUR193 Million, up 13% 3Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 2Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 3
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
SHEEP ANTI BOVINE LACTOPEROXIDASE...
... the ultimate in utility and flexibility press-to-seal ... the needs of the researcher. They are ... or as sheet material that can be ... isolators are autoclavable and non-cytotoxic and can ...
Biology Products: